Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-2 Sublingual Tablet in Acute Ischemic Stroke (TASTE-SL)
NCT04950920Phase 3Completed
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edaravone dexborneol in ischemic stroke, sponsored by Peking University Third Hospital. Started Jun 2021; status: completed.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04950920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950920.